There is much recent interest in utilizing intensified fed-batch culture conditions to increase product yield while maintaining smaller manufacturing size scales. The XD® technology developed by DSM Biologics (now owned by Patheon, part of Thermo Fisher Scientific) is such a system enabling in excess of 200x106 cells/mL and amplifying product yield to approximately 20 g/L. The development of XD® technology is premised on the principle that the product yield increases with the increase in cell growth. While this is true to an extent, there is also the potential that both specific productivity and product quality may be negatively impacted when culturing to such high cell densities. By investigating the growth, metabolic profiles, productivity, and product quality between the XD® and fed-batch processes, understanding of high-density cell cultures may be enhanced.

Intensified fed-batch vs. fed-batch: Is high-density cell culture necessarily better?

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.